We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.

I Agree

You are here: Industry Insights > Maviret

News List

EU Marketing Authorisation change for Maviret pharmatimes
March 10, 2020
The European Commission has granted AbbVie permission to change the Marketing Authorisation for Maviret (glecaprevir/pibrentasvir) to eight weeks of treatment.
European Commission Grants AbbVie Marketing Authorization for Shorter MAVIRET Treatment americanpharmaceuticalreview
March 09, 2020
AbbVie announced that the European Commission has approved a change to the marketing authorization for MAVIRET® (glecaprevir/pibrentasvir) to shorten once-daily treatment duration ...
Cure Hepatitis C in 8 Weeks: Maviret, the Hepatitis C Drug with the Best Efficacy in the World, has Entered China PharmaSources/1℃
June 04, 2019
The National Medical Products Administration of China (NMPA) has approved the marketing of AbbVie’s direct-acting antiviral (DAA) Maviret (glecaprevir/pibrentasvir) on May 15, 2019.